Molecular targeted therapies for pediatric atypical teratoid/rhabdoid tumors

Chang Zhang | Hao Li

ABSTRACT
Atypical teratoid/rhabdoid tumors (AT/RTs) are lethal central nervous system tumors, which are primarily diagnosed in infants. Current treatments for AT/RTs include surgery, radiotherapy, and chemotherapy; these treatments have poor prognoses and challenging side effects. The pivotal genetic event in AT/RT pathogenesis comprises the inactivation of \textit{SMARCB1} or \textit{SMARCA4}. Recent epigenetic studies have demonstrated mutual and subtype-specific epigenetic derangements that drive tumorigenesis; the exploitation of these potential targets might improve the dismal treatment outcomes of AT/RTs. This review aims to summarize the literature concerning targeted molecular therapies for pediatric AT/RTs.

KEYWORDS
Atypical teratoid/rhabdoid tumors, \textit{SMARCB1}, \textit{SMARCA4}, SWI/SNF complex, Targeted molecular therapy

INTRODUCTION
Atypical teratoid/rhabdoid tumors (AT/RTs) in the central nervous system (CNS) are rare and highly aggressive malignancies that tend to occur in infants aged \leq 3 years; such tumors are considered grade 4 in the 2021 World Health Organization Classification of CNS tumors. Current treatment strategies involve intensive multimodality therapies that include surgery, intrathecal and systemic chemotherapy, and radiotherapy; these strategies offer moderate survival improvements but carry the risk of significant treatment-related morbidities.

The genetic landscape of AT/RTs is surprisingly simple: few landmark discoveries have been reported since Sévenet et al. initially reported mutations of the \textit{INI1} (\textit{SMARCB1}) gene in 1999. The genetic hallmark of AT/RTs comprises the inactivation of the \textit{SMARCB1} locus at 22q11.2. In rare cases, \textit{SMARCB1} protein expression is intact in neoplasms with AT/RT features; such neoplasms exhibit inactivation of the \textit{SMARCA4} locus at 19p13. As key components of the SWI/SNF chromatin remodeling complex, \textit{SMARCB1} and \textit{SMARCA4} have been identified in various extracranial tumors (e.g., pediatric malignant RTs and renal medullary carcinoma). SMARCB1 is the most commonly inactivated SWI/SNF complex subunit in mesenchymal neoplasms, while the inactivation of \textit{SMARCA4} has been associated with a greater frequency of germline mutations. Although the specific mechanisms by which \textit{SMARCB1} and \textit{SMARCA4} contribute to AT/RT pathogenesis remain poorly understood, multiple investigations of targeted drugs...
have been inspired by the various pathways and epigenetic deregulation events that result from these simple genetic inactivations.\textsuperscript{10,11}

Considering the rapid development of novel technologies and rapid advances in epigenetics knowledge, this review summarizes recent research concerning targeted therapy for pediatric AT/RTs.

**CURRENT CLINICAL MANAGEMENT OF AT/RTs**

Despite improvements related to the use of aggressive and multimodal therapies during the past decade, survival rates remain poor among patients with AT/RTs. As shown in Table 1, multimodal therapies currently include surgery, chemotherapy (e.g., high-dose chemotherapy [HDC] with peripheral blood stem cell rescue and intrathecal chemotherapy [IT]), radiotherapy, and prompt treatment strategies for specific stages of the disease. Thus far, there is no consensus or standard protocol concerning treatment for AT/RTs.

The survival outcomes of gross total resection (GTR) have varied among studies. A recent study by Richards et al.\textsuperscript{12} demonstrated better survival in the complete total resection group than in the subtotal resection group. A national retrospective study by Lafay-Cousin et al.\textsuperscript{13} showed similarly favorable results; 2-year overall survival (OS) was 60% ± 12.6% in the GTR group. However, other multimodal treatment trials have indicated that GTR does not significantly improve patient prognosis.\textsuperscript{2,3,14} Maximal-safe resection and second-look surgery are recommended as components of multimodal treatment in these trials. However, long-term outcomes cannot be improved solely by increasing the rate of GTR.

In innovations in chemotherapy dose intensity and strategy have gradually improved survival rates among patients with AT/RTs. Slavc et al.\textsuperscript{15} proposed an altered chemotherapy regimen, consisting of three 9-week courses of a dose-dense regimen including doxorubicin, cyclophosphamide, vincristine, ifosfamide, cisplatin, and etoposide followed by IT with methotrexate, HDC, and local radiotherapy to treat patients with AT/RTs. This strategy delayed the requirement for radiotherapy in all included patients; the 5-year OS was 100% and the 5-year event-free survival (EFS) was 88.9% ± 10.5%. Additionally, based on the chemotherapy regimen in Children’s Oncology Group (COG) 99703, the recent clinical trial COG ACNS0333 added methotrexate and HDC during induction and post-induction chemotherapy.\textsuperscript{3} This therapy improved survival (4-year EFS 35%) compared with the historical therapies (4-year EFS 6.4%).\textsuperscript{3} Conversely, a regimen that involved high-dose methotrexate-based induction and myeloablative HDC demonstrated poor outcomes: the 3-year EFS was 21% ± 9% and the 3-year OS was 26% ± 10%.\textsuperscript{16} For patients aged <3 years, chemotherapy that includes HDC with autologous stem cell rescue is considered the main component of multimodal treatment.

The young age of patients with AT/RTs makes radiotherapy challenging: early radiotherapy offers a better prognosis but carries a significant risk of leukoencephalopathy or radiation necrosis, while delayed radiotherapy carries a lower risk of severe CNS complications but tends to allow disease progression.\textsuperscript{17} Additionally, the outcomes of radiotherapy strategies have considerably differed among studies. Some studies have reported a tendency to relapse among patients who receive delayed radiotherapy.\textsuperscript{18–20} Other studies reported that the risks of delayed radiotherapy were negligible among patients who received tailored regimens.\textsuperscript{3,21,22}

After extensive explorations of optimal treatment strategies, survival outcomes have substantially improved among patients with AT/RTs. However, the median OS of patients with AT/RTs is <18 months. Novel therapies are required for patients with AT/RTs, particularly among younger patients and patients with M+ stage tumors.

**MOLECULAR PATHOGENESIS OF AT/RTs**

Epigenetic dysregulation: Chromatin remodeling

The inactivation of \textit{SMARCB1} or \textit{SMARCA4} in AT/RTs results in the loss of their protein products, which are core subunits of the SWI/SNF complex. The SWI/SNF chromatin remodeling complex modifies nucleosome position, thus regulating gene expression through ATP-dependent physical alteration of the chromatin conformation.\textsuperscript{23} The SWI/SNF complexes contain two main units named Brahma/SWI2-related gene 1/Brahma-associated factor (BAF) and polybromo-associated BAF.\textsuperscript{24} \textit{SMARCB1} is a pivotal subunit of BAF that stabilizes the SWI/SNF complex, thus enabling SWI/SNF to bind to the typical enhancer. Therefore, the loss of \textit{SMARCB1} results in the presence of fewer SWI/SNF complexes, reducing the affinity of SWI/SNF for chromatin and preventing the maintenance of normal enhancer function.\textsuperscript{25,26} Alver et al.\textsuperscript{27} reported that reintroduction of \textit{SMARCB1} to \textit{SMARCB1}-knockout cell lines led to widespread recruitment of the SWI/SNF complex to previously unoccupied enhancers, along with activation of these enhancers, and resolution of promoter bivalency toward an active state. Furthermore, Nakayama et al.\textsuperscript{28} found that \textit{SMARCB1} rescue in AT/RTs resulted in increased genome-wide BAF complex occupancy, thereby facilitating widespread enhancer activation. Although the specific functions of \textit{SMARCA4} in AT/RTs remain unclear because \textit{SMARCA4} mutations are rare, Moreno et al.\textsuperscript{29} found that the
### TABLE 1 Latest clinical trials using chemotherapy and radiotherapy for pediatric patients with atypical teratoid/rhabdoid tumors

| Reference          | Time            | Age (years) | M+ | Reference | Time            | Age (years) | M+ | Reference | Time            | Age (years) | M+ |
|--------------------|-----------------|-------------|----|-----------|-----------------|-------------|----|-----------|-----------------|-------------|----|
| Reddy, 2020        | 2008–2017       | <3 (n = 54) | 24 | GTR (n = 25) | ACNS0333 chemotherapy regimen (n = 65) | Focal radiation (n = 28) | 4-year EFS 37% 4-year OS 43% | ACNS0333 regimen improved survival compared with historical therapies for AT/RTs |
|                    |                 | ≥3 (n = 11) |    | NTR (n = 11) | CSI (n = 6) |              |                          |                          |
|                    |                 |             |    | Subtotal, partial, or biopsy (n = 29) |              |                          |                          |                          |
| Yamasaki, 2019     | 2005–2016       | <3 (n = 31) | 23 | GTR (n = 9) | Non-anthraclyne-based regimen (n = 18) | CSI plus local (n = 12) | 2-year OS 66.6% ± 8.3% 2-year PFS 45.9% ± 8.7% 5-year OS 44.2% ± 9.9% 5-year PFS 34.2% ± 8.9% | Multimodal therapy improved outcomes mainly in M0 patients CSI did not improve the prognosis |
|                    |                 | ≥3 (n = 7)  |    | Biopsy (n = 6) | Anthraclyne-based regimen (n = 16) | Local (n = 8) whole brain plus local (n = 1) |                          |                          |
|                    |                 |             |    |            | HDC (n = 19) |              |                          |                          |
| Park, 2021         | 2009–2013       | <3 (n = 43) | 16 | GTR (n = 24) | KSPNO-S052/S082 (n = 18) | Early adjuvant local RT (n = 14) | KSPNO-S052/S082: 3-year PFS 0% KSPNO-S1101: 3-year PFS 47.4% | Early adjuvant RT and HDC improve outcomes of AT/RTs |
|                    |                 |             |    | Subtotal resection (n = 18) | 3-year PFS 47.4% |              |                          |                          |
|                    |                 |             |    | Biopsy (n = 1) | KSPNO-S1101 (n = 24) | Salvage local RT at relapse/progression (n = 13) | CSI at 3 years old (n = 2) |                          |
| Upadhaya, 2021     | SJYC07: 2007–2017 | <3 (n = 52) | 24 | Maximal safe surgical resection (n = 74) | SJYC07-IR (n = 34) | SJYC07-IR: 5-year PFS 31.4% ± 9.2%; OS 43.9% ± 9.5% SJYC07-HR: 5-year PFS and OS 0% SJMB03-AR: 5-year PFS and OS 18.2% ± 9.5% | Post-operative CSI and adjuvant chemotherapy improved outcomes in children with non-metastatic AT/RTs |
|                    | SJMB03: 2003–2013 | ≥3 (n = 22) |    |           | SJYC07-HR (n = 18) |              |                          |                          |
|                    |                 |             |    | Malignant rhabdoid tumor protocol (n = 23) | SJMB03-AR (23.4 Gy CSI) (n = 11) | SJMB03-AR: 5-year PFS and OS 18.2% ± 9.5% |                          |                          |
|                    |                 |             |    | Rhabdomyosarcoma protocol (n = 3) | SJMB03-HR (36–39.6 Gy CSI) (n = 11) | SJMB03-HR: 5-year PFS and OS 0% |                          |                          |
|                    |                 |             |    | Baby brain protocol (n = 1) |              |              |                          |                          |
|                    |                 |             |    | VAC protocol (n = 1) |              |              |                          |                          |
|                    |                 |             |    | VAIA protocol (n = 1) |              |              |                          |                          |
| Mousa, 2021        | 1996–2013       | <3 (n = 30) | 17 | GTR (n = 14) | Malignant rhabdoid tumor protocol (n = 23) | CSI then focal boost (n = 10) | Median OS time: 16.9 months 2-year OS 41.9% ± 9.6% 5-year OS 27.9% ± 9.2% | Postoperative RT and aggressive trimodal therapy are associated with improvement in median survival |
|                    |                 | ≥3 (n = 13) |    | Subtotal resection (n = 23) | Rhabdomyosarcoma protocol (n = 3) | Focal irradiation (n = 7) | Focal irradiation (n = 1) |                          |
|                    |                 |             |    | Biopsy (n = 6) | Baby brain protocol (n = 1) | Palliative irradiation (n = 7) | Palliative irradiation (n = 1) |                          |
|                    |                 |             |    |              | VAC protocol (n = 1) | CSI then focal boost (n = 10) | CSI then focal boost (n = 10) |                          |
|                    |                 |             |    |              | VAIA protocol (n = 1) | Focal irradiation (n = 7) | Focal irradiation (n = 1) |                          |

Abbreviations: AT/RTs, atypical teratoid/rhabdoid tumors; SJYC07, St. Jude Young Children 07; SJMB03, St. Jude Medulloblastoma 03; IR, intermediate risk; AR, average risk; HR, high risk; GTR, gross total resection; NTR, near-total resection; CSI, craniospinal irradiation; EFS, event-free survival; OS, overall survival; PFS, progression-free survival; HDC, high dose chemotherapy; KSPNO: Korean Society for Pediatric Neuro-Oncology; VAC, vincristine, actinomycin-D, and cyclophosphamide; VAIA, vincristine, Adriamycin, Ifosfamide, Actinomycin-D; RT, radiotherapy.
deletion of \textit{SMARCA4} in cerebellar granule cell precursors led to severe proliferation deficits in those cells, along with a hypoplastic cerebellum. \textit{SMARCA4} has similar pro-proliferative functions in the chromatin remodeling complexes of embryonic stem cells.\textsuperscript{30} The mechanisms underlying the dramatic cell proliferation and differentiation consequences related to the loss of \textit{SMARCB1} or \textit{SMARCA4} in SWI/SNF complexes might involve histone modifications.

\textbf{Epigenetic dysregulation: Histone modification}

Global alterations in covalent histone-tail modifications (e.g., acetylation, methylation, and phosphorylation) are frequently observed in cancer, along with aberrant expression patterns of enzymes that mediate these reactions. SWI/SNF complexes can interact with p300 to modulate histone H3 lysine 27 acetylation (H3K27ac), a chromatin marker associated with active chromatin organization and gene transcription; therefore, the loss of \textit{SMARCB1} leads to reduced acetylation of H3K27.\textsuperscript{25} In AT/RT cell lines, Wang et al.\textsuperscript{25} demonstrated that H3K27ac is decreased around specific enhancers that are necessary to control the expression patterns of genes linked to developmental processes. Additionally, the activities of polycomb repressive complex 2 (PRC2) and SWI/SNF are reportedly balanced by distinct modifications of H3K27.\textsuperscript{23} PRC2 is the only mammalian enzyme known to catalyze the methylation of H3K27; it mainly functions through the enhancer of zeste homolog 2 (EZH2) methylase subunit.\textsuperscript{31} Among the methylation products of PRC2, H3K27 trimethylation (H3K27me3) tends to overlap with the absence of H3K27ac in AT/RTs.\textsuperscript{32} Furthermore, ChIP-seq analysis revealed co-localization of \textit{SMARCA4} and EZH2, which indicates that reduced \textit{SMARCA4} activity will lead to increased H3K27me3 and loss of activity among genes that depend on EZH2.\textsuperscript{5}

\textbf{Epigenetic dysregulation: DNA methylation}

The 2021 World Health Organization Classification of CNS Tumors introduced molecular diagnostic criteria into the definitions of AT/RTs, in response to the extensive evidence that specific assortments of molecular alterations have prognostic value and can be used to define distinct tumor types. In 2016, Torchia et al.\textsuperscript{33} analyzed primary AT/RT tissues and cell lines to characterize the genomic and epigenomic landscapes of AT/RTs. Genomewide methylation profiling and RNA sequencing data in subsequent studies have revealed the existence of three molecular subtypes: Notch/sonic hedgehog (ATRT-SHH), tyrosinase enzyme (ATRT-TYR), and \textit{MYC} oncogene (ATRT-MYC).\textsuperscript{33,34} Ho et al.\textsuperscript{35} reanalyzed published methylation array profiles and provided an overview of the molecular characteristics of each AT/RT subtype. The ATRT-SHH subtype (Group I in the work by Torchia et al.\textsuperscript{33}) overexpresses components of the Notch and sonic hedgehog pathways. Gene set enrichment analyses revealed that ATRT-SHH is mainly a neurally differentiated subtype. DNA methylation analyses suggested that the ATRT-SHH subtype could be further stratified according to a mainly supratentorial location (ATRT-SHH-1) or a mainly infratentorial (ATRT-SHH-2) location; tumors in both locations express marker genes from the Notch and SHH pathways. The ATRT-TYR subtype overexpressed tyrosinase, which is essential for neural tube development.\textsuperscript{36,37} Gene set enrichment analysis confirmed that the melanosomal pathway and tyrosine metabolism are enriched in the ATRT-TYR subtype. DNA methylation analyses demonstrated that c-Myb serves as a marker associated with active chromatin organization and gene transcription; therefore, the loss of \textit{SMARCB1} leads to reduced acetylation of H3K27.\textsuperscript{25} In AT/RT cell lines, Wang et al.\textsuperscript{25} demonstrated that H3K27ac is decreased around specific enhancers that are necessary to control the expression patterns of genes linked to developmental processes. Additionally, the activities of polycomb repressive complex 2 (PRC2) and SWI/SNF are reportedly balanced by distinct modifications of H3K27.\textsuperscript{23} PRC2 is the only mammalian enzyme known to catalyze the methylation of H3K27; it mainly functions through the enhancer of zeste homolog 2 (EZH2) methylase subunit.\textsuperscript{31} Among the methylation products of PRC2, H3K27 trimethylation (H3K27me3) tends to overlap with the absence of H3K27ac in AT/RTs.\textsuperscript{32} Furthermore, ChIP-seq analysis revealed co-localization of \textit{SMARCA4} and EZH2, which indicates that reduced \textit{SMARCA4} activity will lead to increased H3K27me3 and loss of activity among genes that depend on EZH2.\textsuperscript{5}

\textbf{Other signaling pathways}

\textbf{Nuclear export signaling}

As a critical mechanism in both tumor and normal tissues, macromolecule transport between the cytoplasm and nucleus offers a novel perspective for AT/RT treatment. The nuclear export of proteins that involves interactions of nuclear export signals with XPO1 is well-known and widely used in targeted therapy research.\textsuperscript{13} XPO1 mediates cell proliferation through the mislocalization of tumor suppressors and stabilization of nuclear and chromosomal structures in tumor cells. Investigations of XPO1 inhibitors of each AT/RT subtype. The ATRT-SHH subtype (Group I in the work by Torchia et al.\textsuperscript{33}) overexpresses components of the Notch and sonic hedgehog pathways. Gene set enrichment analyses revealed that ATRT-SHH is mainly a neurally differentiated subtype. DNA methylation analyses suggested that the ATRT-SHH subtype could be further stratified according to a mainly supratentorial location (ATRT-SHH-1) or a mainly infratentorial (ATRT-SHH-2) location; tumors in both locations express marker genes from the Notch and SHH pathways. The ATRT-TYR subtype overexpressed tyrosinase, which is essential for neural tube development.\textsuperscript{36,37} Gene set enrichment analysis confirmed that the melanosomal pathway and tyrosine metabolism are enriched in the ATRT-TYR subtype. DNA methylation analyses demonstrated that c-Myb serves as a marker associated with active chromatin organization and gene transcription; therefore, the loss of \textit{SMARCB1} leads to reduced acetylation of H3K27.\textsuperscript{25} In AT/RT cell lines, Wang et al.\textsuperscript{25} demonstrated that H3K27ac is decreased around specific enhancers that are necessary to control the expression patterns of genes linked to developmental processes. Additionally, the activities of polycomb repressive complex 2 (PRC2) and SWI/SNF are reportedly balanced by distinct modifications of H3K27.\textsuperscript{23} PRC2 is the only mammalian enzyme known to catalyze the methylation of H3K27; it mainly functions through the enhancer of zeste homolog 2 (EZH2) methylase subunit.\textsuperscript{31} Among the methylation products of PRC2, H3K27 trimethylation (H3K27me3) tends to overlap with the absence of H3K27ac in AT/RTs.\textsuperscript{32} Furthermore, ChIP-seq analysis revealed co-localization of \textit{SMARCA4} and EZH2, which indicates that reduced \textit{SMARCA4} activity will lead to increased H3K27me3 and loss of activity among genes that depend on EZH2.\textsuperscript{5}
have focused on a wide range of cancers, from glioblastoma to pediatric solid tumors.\textsuperscript{44,45}

Pathak et al.\textsuperscript{46} found an unusual cytoplasmic distribution of C-terminally truncated SMARCB1 in AT/RTs. Subsequently, they generated green fluorescent protein fusions of SMARCB1 truncating mutation along with a p.L266A mutation, which has been shown to disrupt the interaction of SMARCB1 nuclear export signals with XPO1. While SMARCB1 with the truncating mutation was localized to the cytoplasm, the double mutant version of SMARCB1 remained in the nucleus; this result indicated that nuclear export signals are required for the cytoplasmic localization of SMARCB1.\textsuperscript{46,47} Furthermore, morphological observations and senescence-associated β-galactosidase assays showed that cells with nuclear SMARCB1 were able to become senescent, while cells with cytoplasmic SMARCB1 were not.\textsuperscript{46} Thus, selective nuclear export signal inhibitors may be useful as targeted therapy for AT/RTs through their ability to prevent cytoplasmic localization of SMARCB1.

**Human endogenous retrovirus K**

HML-2 is a subtype of human endogenous retrovirus K, a repetitive element dispersed throughout the human genome that encodes several intact viral proteins with roles in stem cell maintenance and tumorigenesis.\textsuperscript{48} After SMARCB1 knockdown in neural stem cells, Doucet-O’Hare et al.\textsuperscript{49} found changes in HML-2 env expression in both intracellular and extracellular fractions in AT/RT cell lines; such changes were also present in most AT/RT patient tissues. They also found that SMARCB1 binds a location adjacent to the HML-2 promoter; the restoration of SMARCB1 expression in AT/RT cell lines led to corresponding downregulation of HML-2 expression. Furthermore, targeted downregulation of HML-2 transcription by CRISPR-dCas9-binding repressor proteins led to cellular dispersion, reduced proliferation, and cell death. Finally, HML-2 knockdown led to significant downregulation of Ras expression, suggesting that HML-2 regulates MAPK/ERK signaling in AT/RT cells.\textsuperscript{49} These findings have established a clear connection between AT/RT pathogenesis and the regulation of endogenous retroviral elements; HML-2 offers another promising therapeutic target.

**MOLECULAR TARGETED THERAPIES OF AT/RTS**

For many decades, there was minimal progress regarding targeted therapies for AT/RTs; however, clinical trials involving AT/RT patients have shown significant advances in the past 5 years.

**Mechanisms of targeted therapies**

**Chromatin remodeling and histone modification**

As mentioned in a previous section, SWI/SNF-mediated histone modifications are critical in AT/RT pathogenesis.\textsuperscript{50} Specifically, the acetylation statuses of downstream histones are controlled by histone acetyltransferases and histone deacetylases (HDACs). Histone acetylation presents effective targets for AT/RTs. Kerl et al.\textsuperscript{51} reported that the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA or vorinostat) functioned in a synergistic manner with fenretinide, tamoxifen, and doxorubicin; these effects were confirmed in proliferation assays, apoptosis detection assays, cell cycle analysis, and RNA expression analysis. Further assessments of SAHA in xenograft models revealed that it was an efficient radiosensitizer. Two phase 1 trials using HDAC inhibitor to treat patients with refractory tumors has been completed (Table 2, NCT00217412 and NCt01076530). Other HDAC inhibitors (e.g., panobinostat [LBH589] and resminostat) also have shown favorable pharmacokinetic and pharmacodynamic properties, which might be suitable for treatments in younger children.\textsuperscript{52,53} For example, Muscat et al.\textsuperscript{54} observed terminal differentiation and reduction of the self-renewal ability of malignant RT cells during low-dose panobinostat treatment; this finding was the foundation for a phase 2 trial that is currently recruiting both malignant RT and AT/RT patients (Table 3, NCT04897880). The antagonistic association between SWI/SNF and the PRC2 has an important role in AT/RT pathogenesis, through the regulation of downstream EZH2 and H3K27.\textsuperscript{23} Gene enrichment score analysis showed that a set of H3K27 and EZH2 target genes originated from embryonic stem cells were negatively enriched in RTs, compared with normal brain tissue.\textsuperscript{55} During in vitro analysis, Unland et al.\textsuperscript{56} employed an antagonist for EZH2, 3-deazaneplanocin A (DZNep), alone and in combination with other anticancer drugs (e.g., doxorubicin) or epigenetically active compounds such as the methylation inhibitor 5-AZA-2’-deoxycytidine (5-Aza-CdR) or the HDAC inhibitor SAHA. Proliferation assays in RT cell lines demonstrated that DZNep functioned in a synergistic manner with etoposide, 5-Aza-CdR, and SAHA in terms of antiproliferative function. In a xenograft model, treatment of EZH2-mutant xenografts with tazemetostat (EPZ-6438) caused dose-dependent inhibition of tumor growth, including complete and sustained tumor regression with a corresponding reduction in H3K27me3 levels in both tumors and normal tissues.\textsuperscript{57} An EZH2 inhibitor was beneficial in the treatment of RT xenograft models. This inspired the following clinical experiments using EZH2 inhibitors. In a phase 1 trial that involved refractory non-Hodgkin lymphoma and advanced solid tumor patients, a complete response was achieved in the first RT patient enrolled.\textsuperscript{58} A Phase 2 trial is also ongoing (NCT03213665). One clinical trial of
### TABLE 2 Closed clinical trials of targeted therapy involving patients with atypical teratoid/rhabdoid tumors

| Title and trial ID | Status | Phase | Target drug involved | Molecular mechanism | Starting date |
|--------------------|--------|-------|----------------------|---------------------|--------------|
| SCH 66336 in treating children with recurrent or progressive brain tumors (NCT00015899) | Completed | Phase 1 | Lonafarnib | Farnesyltransferase inhibitor | Jan 1, 2002 |
| Radiolabeled monoclonal antibody therapy in treating patients with refractory, recurrent, or advanced CNS or leptomeningeal cancer (NCT00089245) | Active, not recruiting | Phase 1 | 131I-omburtamab | Anti-GD2 | July 1, 2004 |
| Lenalidomide in treating young patients with recurrent, progressive, or refractory CNS tumors (NCT00100880) | Completed | Phase 1 | Lenalidomide | Immune modulation | Nov 1, 2004 |
| Vorinostat with or without isotretinoin in treating young patients with recurrent or refractory solid tumors, lymphoma, or leukemia (NCT00217412) | Completed | Phase 1 | Vorinostat | Histone deacetylase inhibitor | Aug 1, 2005 |
| Talabostat combined with temozolomide or carboplatin in treating young patients with relapsed or refractory brain tumors or other solid tumors (NCT00303940) | Completed | Phase 1 | Talabostat mesylate | Dipeptidyl peptidase inhibitor | Dec 1, 2005 |
| AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors (NCT00326664) | Completed | Phase 1 | Cediranib maleate | VEGF receptor tyrosine kinases inhibitor | Mar 1, 2006 |
| MK0752 in treating young patients with recurrent or refractory CNS cancer (NCT00572182) | Terminated | Phase 1 | MK-0752 | γ-Secretase inhibitor | Jul 1, 2008 |
| Dasatinib, ifosfamide, carboplatin, and etoposide in treating young patients with metastatic or recurrent malignant solid tumors (NCT00788125) | Active, not recruiting | Phase 1/2 | Dasatinib | Growth factor receptors inhibitor | Sep 3, 2008 |
| Veliparib (ABT-888) and temozolomide in treating young patients with recurrent or refractory CNS tumors (NCT00946335) | Completed | Phase 1 | Veliparib | Poly(ADP-ribose) polymerase inhibitor | Jul 1, 2009 |
| Vorinostat and temozolomide in treating young patients with relapsed or refractory primary brain tumors or spinal cord tumors (NCT01076530) | Completed | Phase 1 | Vorinostat | Histone deacetylase inhibitor | Feb 1, 2010 |
| Gamma-Secretase inhibitor RO4929097 in treating young patients with relapsed or refractory solid tumors, CNS tumors, lymphoma, or T-Cell leukemia (NCT01088763) | Terminated | Phase 1 | RO4929097 | γ-Secretase inhibitor | Mar 1, 2010 |
| Aflac ST0901 CHOANOME-Sirolimus in solid tumors (NCT01311135) | Completed | Phase 1 | Sirolimus | mTOR inhibitor | Apr 1, 2011 |
| p28 in treating younger patients with recurrent or progressive central nervous system tumors (NCT01975116) | Completed | Phase 1 | Azurin-derived cell-penetrating peptide p28 | Peptide inhibitor of p53 ubiquitination | Nov 3, 2013 |
| Simvastatin with topotecan and cyclophosphamide in relapsed and/or refractory pediatric solid and CNS tumors (AflacST1402) (NCT02390843) | Completed | Phase 1 | Simvastatin | Hydroxy-methylglutaryl coenzyme A reductase inhibitor | Mar 18, 2015 |
| A Phase 1 study of the EZH2 inhibitor tazemetostat in pediatric subjects with relapsed or refractory INI1-negative tumors or synovial sarcoma (NCT02601937) | Completed | Phase 1 | Tazemetostat | EZH2 inhibitor | Nov 11, 2015 |
| Ribociclib and everolimus in treating children with recurrent or refractory malignant brain tumors (NCT03387020) | Completed | Phase 1 | Ribociclib Everolimus | CDK4/6 inhibitor mTOR inhibitor | Jan 13, 2018 |

Abbreviations: CDK, cyclin dependent kinase; CNS, central nervous system; EZH2, enhancer of zeste homolog 2; mTOR, mechanistic target of rapamycin kinase; VEGF, vascular endothelial growth factor.
### TABLE 3 Current open targeted therapy clinical trials involving patients with atypical teratoid/rhabdoid tumors

| Title and trial ID                                                                 | Phase | Target drug involved | Molecular mechanism                  | Starting date  |
|-----------------------------------------------------------------------------------|-------|----------------------|--------------------------------------|---------------|
| Phase 2 study of alisertib therapy for rhabdoid tumors (NCT02114229)             | Phase 2 | Alisertib            | Aurora A kinase inhibitor             | May 14, 2014  |
| Sirolimus in combination with metronomic chemotherapy in children with recurrent and/or refractory solid and CNS tumors (NCT02574728) | Phase 2 | Sirolimus            | mTOR inhibitor                        | Jun 1, 2015   |
| Tazemetostat in treating patients with relapsed or refractory advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with EZH2, SMARCB1, or SMARCA4 gene mutations (A Pediatric MATCH Treatment Trial) (NCT03213665) | Phase 2 | Tazemetostat         | EZH2 inhibitor                        | Jul 11, 2017  |
| SJDAWN: St. Jude Children's Research Hospital Phase 1 study evaluating molecularly-driven doublet therapies for children and young adults with recurrent brain tumors (NCT03434262) | Phase 1 | Ribociclib, Sonidegib, Trametinib | CDK4/6 inhibitor, Hedgehog signaling inhibitor, MEK inhibitor | Mar 5, 2018 |
| A study of panobinostat in pediatric patients with solid tumors including MRT/ATRT (NCT04897880) | Phase 2 | Panobinostat         | Histone deacetylase inhibitor         | Jan 9, 2019   |
| Dose escalation study of CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant tumors including but not limited to neuroblastoma, rhabdomyosarcoma, Ewings sarcoma, and osteosarcoma (NCT03478462) | Phase 1 | CLR 131              | Protein kinase B inhibitor            | Apr 30, 2019  |
| Study of nivolumab and ipilimumab in children and young adults with INI1-negative cancers (NCT04416568) | Phase 2 | Nivolumab, Ipilimumab | Anti-PD-1, Anti-CTLA-4               | Aug 14, 2020  |
| Tiragolumab and atezolizumab for the treatment of relapsed or refractory SMARCB1 or SMARCA4 deficient tumors (NCT05286801) | Phase 2 | Atezolizumab, Tiragolumab | Anti-PD-L1, Anti-TIGIT             | Jun 16, 2022  |

Abbreviations: ATRT, atypical teratoid rhabdoid tumor; CDK, cyclin dependent kinase; CNS, central nervous system; EZH2, enhancer of zeste homolog 2; mTOR, mechanistic target of rapamycin kinase; MEK, mitogen-activated extracellular signal-regulated kinase; MRT, malignant rhabdoid tumor; PD-1, programmed cell death protein 1; CTLA-4, Cytotoxic T-lymphocyte associated protein 4; PD-L1, programmed death-ligand 1; TIGIT, T cell immunoreceptor with Ig and ITIM domains.

Tazemetostat in children with AT/RTs and other INI1-negative tumors has been completed, although no results are yet available (NCT02601937).

**Proteasome inhibitors**

Proteasome inhibitors are capable of either directly inducing cancer cell death or sensitizing cancer cells to apoptosis. After high-throughput drug screening with 164 anticancer agents, Nakano et al. found that the proteasome inhibitor bortezomib strongly inhibited AT/RT cell proliferation. Similarly, Thakur et al. tested the cytotoxic effect of another proteasome inhibitor, carfilzomib, using a panel of pediatric solid tumor cell lines that included AT/RTs. Morin et al. showed that marizomib strongly inhibited AT/RT cell growth both in vitro and in vivo; it has direct translational potential for patients with AT/RTs. Because the findings have been derived from sequencing analyses, the cytotoxic mechanisms that underlie the effects of proteasome inhibitors in AT/RT cells remain unclear.

**Cell cycle regulation and associated signaling pathways**

Cyclin D1 is a well-known cell cycle regulator that is reportedly overexpressed in AT/RT cell lines. Although this overexpression was confirmed before the initial recruitment of AT/RT in a clinical trial of the CDK4/6 inhibitor ribociclib (NCT03387020), the link between cyclin D1 expression and SMARCB1 loss was revealed very recently. Xue et al. demonstrated that cyclin D1 deficiency in AT/RTs is caused by SMARCB1 loss partly through the upregulation of MIR17HG, which produces mature miRNAs that target cyclin D1; they also found that this cyclin D1 deficiency in AT/RT cell lines results in considerable sensitivity to the CDK4/6 inhibitor palbociclib.

As mentioned in a previous section, tyrosine kinases are overexpressed in both AT/RT cell lines and primary tumor tissues; of these, the cell cycle-associated serine/threonine kinase aurora A is highly expressed. Similar to HDAC inhibitors, aurora A inhibitors enhance radiosensitivity. The
aurora kinase inhibitor MLN8237 (alisertib) is currently in phase 1/2 clinical trials for various pediatric tumors; it has shown remarkable results. In one trial, four patients with relapsed or refractory AT/RTs were enrolled; all displayed disease stabilization with or without tumor regression.66 Another clinical trial that combines alisertib with conventional therapy in newly diagnosed patients with RTs is in the recruitment stage (Table 3, NCT02114229).

Subtype-specific targeted therapy

Although exclusively subtype-specific drugs are not yet available, subtype susceptibilities to targeted therapy have been demonstrated. For example, platelet-derived growth factor receptor B was identified as a target in Group 2 cell lines (i.e., BT12, BT16, CHLA266, and CHLA06) in the work by Torchia et al.33; these cell lines all exhibited greater sensitivity to the platelet-derived growth factor receptor B inhibitors nilotinib and dasatinib than did Group 1 (ATRT-SHH) cell lines.33 Transcriptome analyses have revealed other potential drug targets in AT/RTs that have not yet been tested in clinical trials. For example, fibroblast growth factor receptor 2 is specifically upregulated in ATRT-TYR, and AT/RTs are susceptible to treatment with fibroblast growth factor receptor inhibition, along with platelet-derived growth factor receptor inhibition.67,68 Notably, Torchia et al.33 reported that cell lines derived from ATRT-SHH tumors were highly sensitive to EZH2 inhibitors. In contrast to the findings in other embryonal tumors (e.g., medulloblastoma), aberrant expression patterns of SHH pathway members have not been found in ATRT-SHH. All changes in SHH pathway marker genes in ATRT-SHH are presumably directly or indirectly caused by the loss of SMARCB1.69 Targeted drugs for SHH pathway inhibitors have diverse therapeutic indications and have demonstrated efficacy for medulloblastoma-SHH; such drugs should be investigated in the treatment of AT/RTs.70 Tran et al.71 reported that, compared with ATRT-SHH cell lines, ATRT-MYC cell lines were more sensitive to the proteasome inhibitor bortezomib. They also found that survival was prolonged in ATRT-MYC patient-derived xenograft mice that received bortezomib, suggesting that bortezomib may function as targeted therapy for ATRT-MYC. However, SMARCA4 has been shown to antagonize MYC activity.72 Taken together, the results of laboratory studies highlight the potential applications of targeted therapies in each molecular subtype.

DISCUSSION

Advances in conventional chemotherapies and stratified treatment protocols have improved the 5-year OS of AT/RTs from 20% to nearly 50%. Nevertheless, most patients with AT/RTs are <3 years of age and have limited treatment options, as well as substantial toxic effects from current regimens. Thus, more effective and less harmful targeted therapies are needed.

Recent studies have shown the potential for treatment by controlling epigenetic dysregulation in AT/RTs. Clinical trials are ongoing for molecular targeted drugs that are designed to function either through the reactivation of enhancers that depend on SWI/SNF complexes or the inhibition of non-SWI/SNF-complex-dependent enhancers; a small amount of AT/RT patients are enrolled in such trials. The good news is that despite the enrollment of AT/RT patients in these trials being scarce, the targeted drugs involved have been designed increasingly specifically for tumorigenesis of AT/RTs over years. Comparing the earlier trials (Table 2) and the ongoing trials (Table 3), it is clear that molecular targets in clinical trials have shifted from usual carcinogenic pathways to AT/RTs-specific pathogenic derangements.

However, most clinical trials of targeted drugs mentioned in this review are based on a larger sample database of patients with RTs or other embryonal CNS tumors; this status highlights the rarity and vulnerability of patients with AT/RTs. Firstly, because of the aggressive malignancy of AT/RTs, patients are barely able to complete the treatment process. Thus, it is difficult to distinguish treatment effects from the vulnerability of advanced patients. Second, because of the rarity of the disease, clinical trials usually lack control. This is another stumbling block to determine the treatment effect. Finally, the toxicity of targeted treatment, though milder than conventional therapies, may exaggerate in these children.

Novel diagnostic criteria indicate the presence of at least three molecular subtypes of AT/RTs: ATRT-TYR, ATRT-SHH, and ATRT-MYC—each has specific or overlapping targeting pathways. The ATRT-SMARCA4 subtype, for which there is no consensus, has great potential for advances in targeted therapeutic research. Notably, AT/RT stratification facilitates targeted drug selection, although it limits patient enrollment in clinical trials, thus prolonging an already time-consuming process. Gene therapy models and national or multicenter AT/RT registries may enable the management of these difficult situations.

Studies of the epigenetic dysregulation mechanism in AT/RT pathogenesis have substantially contributed to targeted therapies over the past decade. Based on the ongoing clinical trials, targeted drugs can provide insights regarding novel multimodal treatment protocols for intractable malignancies.

CONFICT OF INTEREST

The authors declare no conflict of interest.
REFERENCES

1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro Oncol*. 2021;23:1231-1251. DOI: 10.1093/neuonc/noab106

2. Park M, Han JW, Hahn SM, Lee JA, Kim JY, Shin SH, et al. Atypical teratoid/rhabdoid tumor of the central nervous system in children under the age of 3 years. *Cancer Res Treat*. 2021;53:378-388. DOI: 10.4143/crt.2020.756

3. Reddy AT, Brother DR, Judkins AR, Burger PC, Pollack IF, Krailo MD, et al. Efficacy of high-dose chemotherapy and three-dimensional conformal radiation for atypical teratoid/rhabdoid tumor: a report from the children’s oncology group trial ACNS0333. *J Clin Oncol*. 2020;38:1175-1185. DOI: 10.1200/JCO.19.01776

4. Sévenet N, Sheridan E, Amram D, Schneider P, Handgretinger R, Delattre O. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. *Am J Hum Genet*. 1999;65:1342-1348. DOI: 10.1086/302639

5. Erkek S, Johann PD, Finetti MA, Drosos Y, Chou HC, Zapatka M, et al. Comprehensive analysis of chromatin states in atypical teratoid/rhabdoid tumor identifies diverging roles for SWI/SNF and polycomb in gene regulation. *Cancer Cell*. 2019;35:95-110.e8. DOI: 10.1016/j.ccell.2018.11.014

6. Holdhof D, Johann PD, Spohn M, Bockmair M, Saffaei S, Joshi P, et al. Atypical teratoid/rhabdoid tumors (ATRTs) with 5MARCA4 mutation are molecularly distinct from SMARCB1-deficient cases. *Acta Neuropathol*. 2021;141:291-301. DOI: 10.1007/s00401-020-02250-7

7. Del Baldo G, Carta R, Alessi I, Merli P, Agolini E, Rinelli M, et al. Rhabdoid tumor predisposition syndrome: from clinical suspicion to general management. *Front Oncol*. 2021;11:586288. DOI: 10.3389/fonc.2021.586288

8. Nguo C, Postel-Vinay S. Immunotherapy for SMARCB1-deficient sarcomas: current evidence and future developments. *Biomedicines*. 2022;10. DOI: 10.3390/biomedicines10030650

9. Saunders J, Ingleby K, Wang XQ, Harvey M, Armstrong L, Ng T, et al. Loss of BRG1 (SMARCA4) immunorepression in a pediatric non-central nervous system tumor cohort. *Pediatr Dev Pathol*. 2020;23:132-138. DOI: 10.1177/1093526619869154

10. Siada RG, Lu VM, Daniels DJ. Understanding the trajectory of research efforts in atypical teratoid rhabdoid tumors: a bibliometric analysis of the 50 most impactful studies to date. *Childs Nerv Syst*. 2021;37:419-425. DOI: 10.1007/s00381-020-04863-5

11. Nesvick CL, Lafay-Cousin L, Raghunathan A, Bouffet E, Huang AA, Daniels DJ. Atypical teratoid rhabdoid tumor: molecular insights and translation to novel therapeutics. *J Neurooncol*. 2020;150:47-56. DOI: 10.1007/s11060-020-03639-w

12. Richards A, Ved R, Murphy C, Hennigan D, Kilday JP, Kamaly-Asl I, et al. Outcomes with respect to extent of surgical resection for pediatric atypical teratoid rhabdoid tumors. *Childs Nerv Syst*. 2020;36:713-719. DOI: 10.1007/s00381-019-04478-5

13. Lafay-Cousin L, Hawkins C, Carret AS, Johnston D, Zelcer S, Wilson B, et al. Central nervous system atypical teratoid/rhabdoid tumours: the Canadian paediatric brain tumour consortium experience. *Eur J Cancer*. 2012;48:353-359. DOI: 10.1016/j.ejca.2011.09.005

14. Ren YM, Wu X, You C, Zhang YK, Li Q, Ju Y. Multimodal treatments combined with gamma knife surgery for primary atypical teratoid/rhabdoid tumor of the central nervous system: a single-institute experience of 18 patients. *Childs Nerv Syst*. 2018;34:627-638. DOI: 10.1007/s00381-017-3688-3

15. Slavé I, Chocholous M, Leiss U, Haberler C, Peyrl A, Azizi AA, et al. Atypical teratoid rhabdoid tumor: improved long-term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992-2012. *Cancer Med*. 2014;3:91-100. DOI: 10.1002/cam4.161

16. Zaky W, Dhall G, Ji L, Haley K, Allen J, Atlas M, et al. Induction intensive chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: the Head Start III experience. *Pediatr Blood Cancer*. 2014;61:95-101. DOI: 10.1002/pbc.24648

17. Kralik SF, Ho CY, Finke W, Buchsbaum JC, Haskins CP, Shih CS. Radiation necrosis in pediatric patients with brain tumors treated with proton radiotherapy. *AJNR Am J Neuro Radiol*. 2015;36:1572-1578. DOI: 10.3174/ajnr.A4333

18. Pai Panandiker AS, Merchant TE, Beltran C, Wu S, Sharma S, Boop FA, et al. Sequencing of local therapy affects the pattern of treatment failure and survival in children with atypical teratoid rhabdoid tumors of the central nervous system. *Int J Radiat Oncol Biol Phys*. 2012;82:1756-1763. DOI: 10.1016/j.ijrobp.2011.02.059

19. Isikay I, Hanaloglu S, Basar I, Narin F, Bilginer B. Survival benefit with gross total resection and adjuvant radiotherapy in childhood atypical teratoid/rhabdoid tumors: results of a single-center cohort of 27 cases. *Turk Neurosurg*. 2019;29:689-697. DOI: 10.5137/1019-5149.JTN.25406-18.1

20. Chen YW, Wong TT, Ho DM, Huang PI, Chang KP, Shiau CY, et al. Impact of radiotherapy for pediatric CNS atypical teratoid/rhabdoid tumor (single institute experience). *Int J Radiat Oncol Biol Phys*. 2006;64:1038-1043. DOI: 10.1016/j.ijrobp.2005.10.001

21. Yamasaki K, Kiyotani C, Terashima K, Watanebe Y, Kamamori M, Koga Y, et al. Clinical characteristics, treatment, and survival outcome in pediatric patients with atypical teratoid/rhabdoid tumors: a retrospective study by the Japan Children’s Cancer Group. *J Neurosurg Pediatr*. 2019;1:1-10. DOI: 10.3171/2019.9.PEDS19367

22. Park M, Han JW, Hahn SM, Lee JA, Kim JY, Shin SH, et al. Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System in Children under the Age of 3 Years. *Cancer Res Treat*. 2021;53:378-388. DOI: 10.4143/crt.2020.756

23. Kadoch C, Copeland RA, Keilhau H. PRC2 and SWI/SNF chromatin remodeling complexes in health and disease. *Biochemistry*. 2016;55:1600-1614. DOI: 10.1021/acs.biochem.5b01191
24. Panwalkar P, Pratt D, Chung C, Dang D, Le P, Martinez D, et al. SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors. *Neuro Oncol.* 2020;22:785-796. DOI: 10.1093/neuonc/noaa004

25. Wang X, Lee RS, Alver BH, Haswell JR, Wang S, Mieczkowski J, et al. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. *Nat Genet.* 2017;49:289-295. DOI: 10.1038/ng.3746

26. Wang X, Wang S, Troisi EC, Howard TP, Haswell JR, Wolf BK, et al. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors. *Nat Commun.* 2019;10:1881. DOI: 10.1038/s41467-019-09891-7

27. Alver BH, Kim KH, Lu P, Wang X, Manchester HE, Wang W, et al. The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers. *Nat Commun.* 2017;8:14648. DOI: 10.1038/ncomms14648

28. Nakayama RT, Pulice JI, Valencia AM, McBride MJ, McKenzie ZM, Gillespie MA, et al. SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters. *Nat Genet.* 2017;49:1613-1623. DOI: 10.1038/ng.3958

29. Moreno N, Schmidt C, Ahlfeld J, Poschl J, Dittmar S, Pfister SM, et al. Loss of Smarc proteins impairs cerebellar development. *J Neurosci.* 2014;34:13486-13491. DOI: 10.1523/JNEUROSCI.2560-14.2014

30. Ho L, Miller EL, Ronan JL, Ho WQ, Jothi R, Crabtree GR. esBFA facilitates pluripotency by conditioning the genome for LIF/STAT3 signalling and by regulating polycomb function. *Nat Cell Biol.* 2011;13:903-913. DOI: 10.1038/ncb2285

31. Lee CH, Yu JR, Granat J, Saldaña-Meyer R, Andrade J, LeRoy G, et al. Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma. *Genes Dev.* 2019;33:1428-1440. DOI: 10.1101/gad.328773.119

32. Wang X, Sansam CG, Thom CS, Metzger D, Evans JA, Nguyen PT, et al. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. *Cancer Res.* 2009;69:8094-8101. DOI: 10.1158/0008-5472.CAN-09-0733

33. Torchia J, Golbourn B, Feng S, Ho KC, Sin-Chan P, Vasiljevic A, et al. Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors. *Cancer Cell.* 2016;30:891-908. DOI: 10.1016/j.ccell.2016.11.003

34. Johann PD, Erkek S, Zapatka M, Kerl K, Buchhalter I, Hovestadt V, et al. Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. *Cancer Cell.* 2016;29:379-393. DOI: 10.1016/j.ccell.2016.02.001

35. Ho B, Johann PD, Grabovska Y, De Dieu Andrianteranagna MJ, Yao F, Frühwald M, et al. Molecular subgrouping of atypical teratoid/rhabdoid tumors-a re-investigation and current consensus. *Neuro Oncol.* 2020;22:613-624. DOI: 10.1093/neuonc/noz235

36. Hasselblatt M, Thomas C, Nemes K, Monoranu CM, Riemenschneider MJ, Koch A, et al. Tyrosinase immuno-histochemistry can be employed for the diagnosis of atypical teratoid/rhabdoid tumours of the tyrosinase subgroup (ATRT-TYR). *Neuropathol Appl Neurobiol.* 2020;46:186-189. DOI: 10.1111/nan.12560

37. Simões-Costa M, Bronner ME. Establishing neural crest identity: a gene regulatory recipe. *Development.* 2015;142:242-257. DOI: 10.1242/dev.105445

38. Johann PD, Hovestadt V, Thomas C, Jeibmann A, Heß K, Bens S, et al. Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. *Brain Pathol.* 2017;27:411-418. DOI: 10.1111/bpa.12413

39. Kling T, Wenger A, Carén H. DNA methylation-based age estimation in pediatric healthy tissues and brain tumors. *Aging.* 2020;12:21037-21056. DOI: 10.18632/aging.202145

40. Liu F, Fan S, Tang X, Fan S, Zhou L. Adult sellar region atypical teratoid/rhabdoid tumor: a retrospective study and literature review. *Front Neuro.* 2020;11:604612. DOI: 10.3389/fneur.2020.604612

41. Alimova I, Pierce A, Danis E, Donson A, Birks DK, Griesinger A, et al. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo. *Int J Cancer.* 2019;144:1983-1995. DOI: 10.1002/ijc.31873

42. Wang SZ, Poore B, Alt J, Price A, Allen SJ, Hanaford AR, et al. Unbiased metabolic profiling predicts sensitivity of high MYC-expressing atypical teratoid/rhabdoid tumors to glutamine inhibition with 6-diazo-5-oxo-l-norleucine. *Clin Cancer Res.* 2019;25:5925-5936. DOI: 10.1158/1078-0432.CCR-19-0189

43. Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C. Nucleo-cytoplasmic transport as a therapeutic target of cancer. *J Hematol Oncol.* 2014;7:85. DOI: 10.1186/s13045-014-0085-1

44. Green AL, Ramkisson SH, McCauley D, Jones K, Perry JA, Hsu JH, et al. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. *Neuro Oncol.* 2015;17:697-707. DOI: 10.1093/neuonc/nou303

45. Sun Q, Chen X, Zhou Q, Burstein E, Yang S, Jia D. Inhibiting cancer cell hallmark features through nuclear export inhibition. *Signal Transduct Target Ther.* 2016;1:16010. DOI: 10.1038/sigtrans.2016.10

46. Pathak R, Zin F, Thomas C, Bens S, Gayden T, Karamchandani J, et al. Inhibition of nuclear export restores nuclear localization and residual tumor suppressor function of truncated SMARCB1/INI1 protein in a molecular subset of atypical teratoid/rhabdoid tumors. *Acta Neuropathol.* 2021;142:361-374. DOI: 10.1007/s00401-021-02328-w

47. Valencia AM, Collings CK, Diao HT, St Pierre R, Cheng YM, Huang J, et al. Recurrent SMARCB1 mutations reveal a nucleosome acidic patch interaction site that potentiates mSWI/SNF complex chromatin remodeling. *Cell.* 2019;179:1342-1356.e23. DOI: 10.1016/j.cell.2019.10.044

48. Okahara G, Matsubara S, Oda T, Sugimoto J, Jinno Y, Kanaya F. Expression analyses of human endogenous retroviruses (HERVs): tissue-specific and developmental stage-dependent expression of HERVs. *Genomics.* 2004;84:982-990. DOI: 10.1016/j.ygeno.2004.09.004
49. Doucet-O’Hare TT, Hare TT, DiSanza BL, DeMarino C, Atkinson AL, Rosenblum JS, et al. SMARCB1 deletion in atypical teratoid rhabdoid tumors results in human endogenous retrovirus K (HML-2) expression. Sci Rep. 2021;11:12893. DOI: 10.1038/s41598-021-92223-x

50. Helming KC, Wang X, Roberts C. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell. 2014;26:309-317. DOI: 10.1016/j.ccr.2014.07.018

51. Kerl K, Ries D, Unland R, Borchert C, Moreno N, Hasselblatt M, et al. The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells. BMC Cancer. 2013;13:286. DOI: 10.1186/1471-2407-13-286

52. Sharma S, Witteveen PO, Lokkema MP, Hess D, Gelderblom H, Hussain S, et al. A phase I open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer Chemother Pharmacol. 2015;75:87-95. DOI: 10.1007/s00280-014-2612-8

53. Tak WY, Ryoo BY, Lim HY, Kim DY, Okusaka T, Ikeda M, et al. Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. Invest New Drugs. 2018;36:1072-1084. DOI: 10.1007/s10637-018-0658-x

54. Muscat A, Popovski D, Jayasekara WS, Rossello FJ, Ferguson M, Marini KD, et al. Low-dose histone deacetylase inhibitor treatment leads to tumor growth arrest and multi-lineage differentiation of malignant rhabdoid tumors. Clin Cancer Res. 2016;22:3560-3570. DOI: 10.1158/1078-0432.CCR-15-2260

55. Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho YJ, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell. 2010;18:316-328. DOI: 10.1016/j.ccr.2010.09.006

56. Unland R, Borchardt C, Clemens D, Kool M, Dirksen U, Frühwald MC. Analysis of the antiproliferative effects of 3-deazaneplanocin A in combination with standard anti-cancer agents in rhabdoid tumor cell lines. Anticancer Drugs. 2015;26:301-311. DOI: 10.1097/CAD.000000000000181

57. Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. 2014;13:842-854. DOI: 10.1158/1535-7163.MCT-13-0773

58. Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumors: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018;19:649-659. DOI: 10.1016/S1470-2245(18)30145-1

59. Nakano Y, Takadera M, Miyazaki M, Qiao Z, Nakajima K, Noguchi R, et al. Drug screening with a novel tumor-derived cell line identified alternative therapeutic options for patients with atypical teratoid/rhabdoid tumor. Hum Cell. 2021;34:271-278. DOI: 10.1016/j.scr.2020-00438-3

60. Thakur S, Ruan Y, Jayanthan A, Boklan J, Narendran A. Cytotoxicity and target modulation in pediatric solid tumors by the proteasome inhibitor carfilzomib. Curr Drug Targets. 2021;21:804-811. DOI: 10.2174/1568096216666201504085527

61. Morin A, Soane C, Pierce A, Sanford B, Jones KL, Crespo M, et al. Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors. Neurooncol Adv. 2020;2:vdaa051. DOI: 10.1093/noajnl/vdaa051

62. Fujisawa H, Misaki K, Takabatake Y, Hasegawa M, Yamashita J. Cyclin D1 is overexpressed in atypical teratoid/rhabdoid tumor with hSNF5/INI1 gene inactivation. J Neurooncol. 2005;73:117-124. DOI: 10.1007/s11060-004-4276-4

63. McKenna ES, Sansam CG, Cho YJ, Greulich H, Evans JA, Thom CS, et al. Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Mol Cell Biol. 2008;28:6223-6233. DOI: 10.1128/MCB.00658-08

64. Xue Y, Zhu X, Meehan B, Venneti S, Martinez D, Morin G, et al. SMARCB1 loss induces druggable cyclin D1 deficiency via upregulation of MIR17HG in atypical teratoid rhabdoid tumors. J Pathol. 2020;252:77-87. DOI: 10.1002/path.5493

65. Lee S, Cimica V, Ramachandra N, Zagzag D, Kalpana GV. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival. Cancer Res. 2011;71:3225-3235. DOI: 10.1158/0008-5472.CAN-10-2167

66. Wetmore C, Boyett J, Li S, Lin T, Bendel A, Gajjar A, et al. Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. Neuro Oncol. 2015;17:882-888. DOI: 10.1093/neuonc/nov107

67. Wong JP, Todd JR, Finet MA, McCarthy F, Broncel M, Vyse S, et al. Dual targeting of PDGFRα and FGFR1 displays synergistic efficacy in malignant rhabdoid tumors. Cell Rep. 2016;17:1265-1275. DOI: 10.1016/j.celrep.2016.10.005

68. Chauvin C, Leruste A, Taziede-Espariat A, Andrianteranagna M, Surdez D, Lescure A, et al. High-throughput drug screening identifies pazopanib and clofilium tosylate as promising treatments for malignant rhabdoid tumors. Cell Rep. 2017;21:1737-1745. DOI: 10.1016/j.celrep.2017.10.076

69. Jagani Z, Mora-Blanco EL, Narashima SG, McKenna ES, Wilson B, Chen D, et al. Loss of the tumor suppressor SNF5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med. 2010;16:1429-1433. DOI: 10.1038/nm.2251

70. Kerl K, Moreno N, Holsten T, Ahlfeld J, Mertins J, Hotfilder M, et al. Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1. Int J Cancer. 2014;135:989-995. DOI: 10.1002/ijc.28719

71. Tran HM, Wu KS, Sung SY, Changou CA, Hsieh TH, Liu YR, et al. Upregulation of protein synthesis and proteasome degradation confers sensitivity to proteasome inhibitor bortezomib in myc-atypical teratoid/rhabdoid tumors. Cancers. 2020;12. DOI: 10.3390/cancers12030752

72. Romero OA, Setien F, John S, Gimenez-Xavier P, Gomez-Lopez G, Pisano D, et al. The tumour suppressor and chromatin-remodelling mediator BRG1 antagonizes Myc...
activity and promotes cell differentiation in human cancer. *EMBO Mol Med.* 2012;4:603-616. DOI: 10.1002/emmm.201200236

73. Upadhyaya SA, Robinson GW, Onar-Thomas A, Orr BA, Johann P, Wu G, et al. Relevance of molecular groups in children with newly diagnosed atypical teratoid rhabdoid tumor: results from prospective St. Jude multi-institutional trials. *Clin Cancer Res.* 2021;27:2879-2889. DOI: 10.1158/1078-0432.CCR-20-4731

74. Mousa A, Al-Kofide A, Siddiqui K, Alhindi H, Alshaikh N, Alshail E. Atypical teratoid rhabdoid tumors (ATRT): King Faisal Specialist Hospital and Research Centre experience. *Int J Pediatr Adolesc Med.* 2021;8:154-159. DOI: 10.1016/j.ijpam.2020.06.004

75. Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, et al. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. *J Clin Oncol.* 2007;25:3137-3143. DOI: 10.1200/JCO.2006.09.4243

76. Warren KE, Goldman S, Pollack IF, Fangusaro J, Schaiquevich P, Stewart CF, et al. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: pediatric brain tumor consortium study PBTC-018. *J Clin Oncol.* 2011;29:324-329. DOI: 10.1200/JCO.2010.31.3601

77. Meany H, Balis FM, Aikin A, Whitcomb P, Murphy RF, Steinberg SM, et al. Pediatric phase I trial design using maximum target inhibition as the primary endpoint. *J Natl Cancer Inst.* 2010;102:909-912. DOI: 10.1093/jnci/djq174

78. Kieran MW, Chi S, Goldman S, Onar-Thomas A, Poussaint TY, Vajapeyam S, et al. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. *Childs Nerv Syst.* 2015;31:1433-1445. DOI: 10.1007/s00381-015-2812-5

79. Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. *J Clin Oncol.* 2011;29:3529-3534. DOI: 10.1200/JCO.2011.35.7806

80. Su JM, Thompson P, Adesina A, Li XN, Kilburn L, Onar-Thomas A, et al. Phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report. *Neuro Oncol.* 2014;16:1661-1668. DOI: 10.1093/neuonc/nou103

81. Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, et al. A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children’s Oncology Group phase 1 consortium study. *Pediatr Blood Cancer.* 2011;67:e28134. DOI: 10.1002/pbc.28134

82. Qayed M, Cash T, Tighiouart M, MacDonald TJ, Goldsmith KC, Tanos R, et al. A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors. *Pediatr Blood Cancer.* 2020;67:e28134. DOI: 10.1002/pbc.28134

83. DeWire MD, Fuller C, Campagne O, Lin T, Pan H, Young Poussaint T, et al. A phase I and surgical study of ribociclib and everolimus in children with recurrent or refractory malignant brain tumors: a pediatric brain tumor consortium study. *Clin Cancer Res.* 2021;27:2442-2451. DOI: 10.1158/1078-0432.CCR-20-4078

How to cite this article: Zhang C, Li H. Molecular targeted therapies for pediatric atypical teratoid/rhabdoid tumors. *Pediatr Investig.* 2022;6:111–122. https://doi.org/10.1002/ped4.12325